Turner Investments
1000 Chesterbrook Blvd, Suite 135, Berwyn, PA, 19312, United States
Overview
Turner Investments manages growth, global/international, and alternative separately managed accounts and mutual funds. We define ourselves in three ways. One, our culture is one of collaboration and accountability. Two, our research is conducted by investment teams that focus on specific market sectors. And three, we embrace innovation -- we are open to new ideas. In 1990 we started Turner Investments in Berwyn, Pennsylvania, in a cramped office with a few computers and low overhead. Staff members took little or no compensation that first year. Original staffers included two brothers, Bob and Mark Turner, and Chris McHugh. (Bob is now chairman and chief investment officer, Mark is president and senior portfolio manager, and Chris is vice chairman and senior portfolio manager.) As Mark notes, “We saw an opportunity and thought of doing something on our own. Our biggest advantage was our naiveté; we didn’t recognize the pitfalls of starting a business. We had enough assets under management to keep the lights on and pay the bills.” By the end of the first year, however, our assets under management totaled $112 million, and we were on our way. Today we manage approximately $10.7 billion (as of December 31, 2012).
- Total investments
- 1
- Lead investments
- 0
- Investments · 12mo
- 0
- Active investors
- 2
Sector focus
- Collaboration
- Financial Services
Investment portfolio
- Rimidi
Participated · Series A · Jul 2018
Rimidi provides a platform that aggregates patient-generated data, clinical information, and practice guidelines to enable clinicians to personalize care and identify individuals who may benefit from specific therapeutic approaches. The solution integrates with electronic medical record systems to deliver a workflow experience for clinicians at the point of care. The company focuses on chronic disease management and offers clinical analytics and software to support care teams. Led by CEO Josh Claman and formerly known as Rimidi Diabetes, the company is based in Atlanta, GA. Rimidi closed a $6.575M Series A-1 financing from investors including Eli Lilly, Turner Investments, Cox Enterprises, Village Capital, The Jump Fund and JAMB Global. It intends to use the proceeds to accelerate growth and market penetration. Rimidi develops a cloud-based platform for diabetes and chronic disease management. Led by CEO Lucienne Ide, its flagship product, Diabetes+Me™, lets patients track health and lifestyle data and access medical and nutritional information. Care teams leverage the platform’s proprietary analytics for treatment decision-making, population management and improved care. The company said it will use the newly received funds to expand into additional markets. The amount of the investment was not disclosed. Rimidi previously received funding from SOURCE (a partnership between the Hitachi Foundation, Investor’s Circle and Village Capital) and the JumpFund.
Team
Robert Turner
Co-Founder & Chief Investment Officer
LinkedInStefania Perrucci
Global Head of Fixed Income